About

Dr. Manasi Jaiman has served as Aardvark's Chief Medical Officer since September 2024. From October 2022 to March 2024 she was Vice President, Clinical Development and Platform Lead at Vertex Pharmaceuticals (Nasdaq: VRTX), and from 2020 to 2023 she served in various roles at ViaCyte, Inc., including Chief Medical Officer and Vice President of Clinical Development, developing novel cell-therapy approaches. She was previously Senior Medical Director at Covance/LabCorp and, from 2014 to 2020, an attending physician at Harvard Medical School and Massachusetts General Hospital caring for pediatric endocrinology patients, including those with Prader-Willi syndrome. Dr. Jaiman received her M.D. from the Medical University of South Carolina, her M.P.H. from Tulane University, and a B.S. in Psychology from the University of South Carolina Honors College.

Roles

Aardvark Therapeutics, Inc.
Chief Medical Officer · Current role
September 2024–present
Aardvark Therapeutics, Inc.
Chief Medical Officer
September 2024 - present
Vertex Pharmaceuticals Incorporated
Vice President, Clinical Development and Platform Lead
2022 - 2024
ViaCyte, Inc.
Chief Medical Officer / Vice President, Clinical Development
2020 - 2023
Covance/LabCorp
Senior Medical Director
Harvard Medical School / Massachusetts General Hospital
Attending Physician, Pediatric Endocrinology
2014 - 2020

Fixed Compensation

FY 2025
Salary
$495,962
ComponentAnnual base salary earned in 2025
Total compensation
$1,870,053

Performance Compensation

Data from FY 2025

Cash incentive

Non-equity incentive plan compensation
$197,077
Target Opportunity
PlanAnnual performance-based cash bonus

Stock awards

Option awards
$1,177,014
FormStock options, ASC 718 grant-date fair value

Also at Aardvark Therapeutics, Inc.

Related

See how VectorShift works for your firm

Request Demo